Published in Br J Cancer on October 01, 1988
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer (1991) 1.37
The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer (1991) 1.35
Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci U S A (1995) 1.32
c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer (1991) 1.30
Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells. Mol Cell Biol (1990) 1.26
An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer (1989) 1.23
The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res (2003) 1.20
Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1992) 1.14
Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol (1997) 1.07
C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer (1990) 1.04
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer (1991) 1.04
Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol (2007) 0.99
c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol (1992) 0.98
c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol (1991) 0.96
c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer (1989) 0.96
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Mol Pathol (2001) 0.87
Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer (1996) 0.86
Apocrine adenosis: a precursor of aggressive breast cancer? J Clin Pathol (1995) 0.86
Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats. Am J Pathol (1999) 0.84
Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer (1993) 0.83
c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer (1997) 0.81
Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am J Pathol (1996) 0.77
C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast. Bosn J Basic Med Sci (2012) 0.75
The PR status of the originating cell of ER/PR-negative mouse mammary tumors. Oncogene (2015) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell (1986) 7.06
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (1986) 5.77
Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J (1987) 4.33
Sevenless, a cell-specific homeotic gene of Drosophila, encodes a putative transmembrane receptor with a tyrosine kinase domain. Science (1987) 3.06
Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol (1987) 2.96
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene (1987) 2.67
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet (1987) 2.44
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell (1982) 2.22
Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep (1984) 1.77
Localization of the sevenless protein, a putative receptor for positional information, in the eye imaginal disc of Drosophila. Cell (1987) 1.75
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res (1987) 1.70
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A (1986) 1.56
Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes (1987) 1.00
In situ intraduct carcinoma of the breast: a long term follow-up study. Br J Surg (1975) 0.99
No hiding place: on the discomforts of researching the contemporary policy process. J Soc Policy (1990) 8.97
Compensation for a bad start: grow now, pay later? Trends Ecol Evol (2001) 8.49
Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell (1991) 5.84
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Expression of the CD34 gene in vascular endothelial cells. Blood (1990) 4.41
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Legitimate double-think. Lancet (1993) 4.31
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Screening for asymptomatic urinary-tract infection in schoolgirls. A two-centre feasibility study. Lancet (1973) 3.10
It's about more than money: financial incentives and internal motivation. Qual Saf Health Care (2005) 3.09
Experimental demonstration that offspring sex ratio varies with maternal condition. Proc Natl Acad Sci U S A (1999) 2.90
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet (1990) 2.77
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
To the point of farce: a Martian view of the Hardinian taboo--the silence that surrounds population control. BMJ (1997) 2.68
The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys (1994) 2.65
Helping health professionals involved in cancer care acquire key interviewing skills--the impact of workshops. Eur J Cancer (1996) 2.62
Resource allocation between reproductive phases: the importance of thermal conditions in determining the cost of incubation. Proc Biol Sci (2000) 2.62
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet (1987) 2.44
Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci (2002) 2.43
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res (1986) 2.38
Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med (2000) 2.36
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res (1988) 2.36
Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res (1993) 2.35
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet (1998) 2.27
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Second opinions: a right or a concession? BMJ (1995) 2.25
Health needs assessment. Whose priorities? Listening to users and the public. BMJ (1998) 2.19
Pulling the plug on futility. BMJ (1995) 2.19
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Helping cancer patients disclose their concerns. Eur J Cancer (1996) 2.11
Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J Infect Dis (2001) 2.11
Risk prediction in coronary artery surgery: a comparison of four risk scores. Med J Aust (1997) 2.10
Primary biliary cirrhosis is associated with falls and significant fall related injury. QJM (2010) 2.08
Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer (1985) 2.08
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Purification and characterization of vaccinia virus growth factor. Cell (1985) 2.06
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet (2000) 1.96
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol (2003) 1.92
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2004) 1.87
Goblet cell carcinoid of the appendix. Cancer (1974) 1.81
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (1973) 1.81
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Antitussive activity of iodo-resiniferatoxin in guinea pigs. Thorax (2004) 1.73
Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer (1981) 1.70
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene (1990) 1.69
Guidelines for compatibility procedures in blood transfusion laboratories. Transfus Med (2004) 1.67
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer (2006) 1.66
Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1. J Virol Methods (2007) 1.66
Evolution of the structural proteins of human immunodeficiency virus: selective constraints on nucleotide substitution. AIDS Res Hum Retroviruses (1988) 1.65
Implementing a community-based social marketing project to improve agricultural worker health. Environ Health Perspect (2001) 1.64
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res (2000) 1.63
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (1992) 1.63
Cell-autonomous expression of barley Mla1 confers race-specific resistance to the powdery mildew fungus via a Rar1-independent signaling pathway. Plant Cell (2001) 1.62
Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci (2001) 1.62
Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene (1992) 1.62
A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng (1990) 1.62
Tamoxifen for the prevention of breast cancer. Eur J Cancer (2000) 1.62
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol (2001) 1.61
Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfus Med (2012) 1.60
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol (1991) 1.58
Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. Soc Sci Med (2001) 1.58
Neu receptor dimerization. Nature (1989) 1.58
Surgical experience and supervision may influence the quality of lower limb amputation. Ann R Coll Surg Engl (2002) 1.57
The epidermal growth factor receptor family. Endocr Relat Cancer (2005) 1.55
Short-term results of femoropopliteal subintimal angioplasty. Br J Surg (2000) 1.54
Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. Histopathology (1989) 1.53
Incidence and significance of argentaffin and paneth cells in some tumours of the large intestine. J Clin Pathol (1967) 1.53
UNICEF's call to greatness--an open letter to Ms Carol Bellamy, Executive Director, United Nations Children's Fund. Natl Med J India (1996) 1.51
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Adult-to-adult living donor liver transplantation for fulminant hepatic failure. Med J Aust (2001) 1.50
Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol (R Coll Radiol) (2000) 1.49
Immunohistochemical detection of the c-erbB-2 proto-oncogene product in normal, benign and malignant cartilage tissues. Histopathology (1989) 1.48
Biochemical markers in human breast cancer. Lancet (1977) 1.48
Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol. Br J Cancer (1998) 1.48
The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci (2005) 1.46